Compare Stocks: NKTR, PTCT, ORKA, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRM Mirum Pharmaceuticals	$86.06 +0.1%	$94.71	$63.23 ▼ $130.00	$5.58B	0.61	917,207 shs	1.21 million shs
NKTR Nektar Therapeutics	$39.84 -3.2%	$66.54	$33.40 ▼ $109.00	$1.41B	1.26	2.03 million shs	1.05 million shs
ORKA Oruka Therapeutics	$80.35 -2.1%	$94.29	$24.46 ▼ $115.51	$5.44B	-0.37	1.09 million shs	547,918 shs
PTCT PTC Therapeutics	$62.92 -2.8%	$68.26	$61.23 ▼ $90.87	$5.40B	0.49	1.33 million shs	745,204 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRM Mirum Pharmaceuticals	0.00%	+3.71%	-12.43%	-27.75%	+18.29%
NKTR Nektar Therapeutics	0.00%	-5.53%	-40.98%	-39.74%	-24.24%
ORKA Oruka Therapeutics	0.00%	-2.85%	-11.12%	-2.90%	+235.28%
PTCT PTC Therapeutics	0.00%	+1.95%	-2.06%	-20.45%	-2.31%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MIRM Mirum Pharmaceuticals	$86.06 +0.1%	$94.71	$63.23 ▼ $130.00	$5.58B	0.61	917,207 shs	1.21 million shs
NKTR Nektar Therapeutics	$39.84 -3.2%	$66.54	$33.40 ▼ $109.00	$1.41B	1.26	2.03 million shs	1.05 million shs
ORKA Oruka Therapeutics	$80.35 -2.1%	$94.29	$24.46 ▼ $115.51	$5.44B	-0.37	1.09 million shs	547,918 shs
PTCT PTC Therapeutics	$62.92 -2.8%	$68.26	$61.23 ▼ $90.87	$5.40B	0.49	1.33 million shs	745,204 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MIRM Mirum Pharmaceuticals	0.00%	+3.71%	-12.43%	-27.75%	+18.29%
NKTR Nektar Therapeutics	0.00%	-5.53%	-40.98%	-39.74%	-24.24%
ORKA Oruka Therapeutics	0.00%	-2.85%	-11.12%	-2.90%	+235.28%
PTCT PTC Therapeutics	0.00%	+1.95%	-2.06%	-20.45%	-2.31%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$145.63	69.21% Upside
NKTR Nektar Therapeutics	2.69	Moderate Buy	$130.67	227.98% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$128.91	60.43% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$98.25	56.15% Upside

Current Analyst Ratings Breakdown

Latest NKTR, PTCT, ORKA, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/12/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$152.00
10/12/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$53.00
10/12/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$160.00 ➝ $184.00
10/12/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$195.00 ➝ $200.00
10/12/2026	NKTR Nektar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$130.00
10/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
10/9/2026	NKTR Nektar Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform
10/8/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
10/8/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$135.00 ➝ $155.00
10/7/2026	ORKA Oruka Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MIRM Mirum Pharmaceuticals	$521.31M	10.72	$0.05 per share	1,687.16	$6.12 per share	14.06
NKTR Nektar Therapeutics	$55.23M	24.63	N/A	N/A	$4.41 per share	9.03
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A
PTCT PTC Therapeutics	$1.73B	3.03	$8.54 per share	7.37	($2.56) per share	-24.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	30.69	1.95	-3.80%	N/A	-1.32%	11/3/2026 (Estimated)

Latest NKTR, PTCT, ORKA, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	NKTR Nektar Therapeutics	-$2.08	N/A	N/A	N/A	$10.31 million	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.53	N/A	N/A	N/A	$178.06 million	N/A
11/3/2026	Q3 2026	PTCT PTC Therapeutics	$0.2789	N/A	N/A	N/A	$302.83 million	N/A
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
NKTR Nektar Therapeutics	N/A	10.42	10.42
ORKA Oruka Therapeutics	N/A	38.51	38.51
PTCT PTC Therapeutics	N/A	3.39	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MIRM Mirum Pharmaceuticals	N/A
NKTR Nektar Therapeutics	75.88%
ORKA Oruka Therapeutics	56.44%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
MIRM Mirum Pharmaceuticals	8.32%
NKTR Nektar Therapeutics	2.50%
ORKA Oruka Therapeutics	23.49%
PTCT PTC Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A
PTCT PTC Therapeutics	991	83.46 million	79.04 million	Optionable

NKTR, PTCT, ORKA, and MIRM Headlines

Recent News About These Companies

PTC Therapeutics (NASDAQ:PTCT) Director Sells $158,475.00 in Stock

October 12 at 4:09 AM | americanbankingnews.com

PTC Therapeutics (PTCT) Gets a Hold from RBC Capital

October 10 at 9:02 AM | theglobeandmail.com

PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Michael Schmertzler Sells 2,500 Shares

October 10 at 5:52 AM | insidertrades.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 10 at 2:15 AM | americanbankingnews.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages

October 10 at 2:13 AM | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock Gets Downgrade from Wall Street Zen

October 10 at 1:23 AM | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock

October 9 at 7:07 PM | marketbeat.com

RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating

October 8, 2026 | marketscreener.comM

PTC Therapeutics (NASDAQ:PTCT) VP Sells 435 Shares of Company Stock

October 8, 2026 | insidertrades.com

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock

October 7, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares

October 7, 2026 | marketbeat.com

PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says

October 7, 2026 | marketscreener.comM

Cantor raises target for PTC Therapeutics stock to USD 137.00

October 7, 2026 | ad-hoc-news.deA

PTC Therapeutics (NASDAQ:PTCT) Director Glenn Md Phd Steele, Jr. Sells 12,000 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells 12,000 Shares of Stock

October 3, 2026 | insidertrades.com

PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock

October 2, 2026 | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7% - Here's What Happened

September 28, 2026 | marketbeat.com

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 25, 2026 | prnewswire.com

PTC Therapeutics, Inc.: PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy

September 22, 2026 | finanznachrichten.de

PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4

September 22, 2026 | rttnews.com

Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00

September 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, PTCT, ORKA, and MIRM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

$86.06 +0.05 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$86.08 +0.02 (+0.03%)

As of 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Nektar Therapeutics NASDAQ:NKTR

$39.84 -1.33 (-3.23%)

Closing price 04:00 PM Eastern

Extended Trading

$40.12 +0.28 (+0.70%)

As of 07:30 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Oruka Therapeutics NASDAQ:ORKA

$80.35 -1.76 (-2.14%)

Closing price 04:00 PM Eastern

Extended Trading

$80.71 +0.36 (+0.45%)

As of 07:30 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

PTC Therapeutics NASDAQ:PTCT

$62.92 -1.78 (-2.75%)

Closing price 04:00 PM Eastern

Extended Trading

$62.93 +0.01 (+0.02%)

As of 07:30 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTR, PTCT, ORKA, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTR, PTCT, ORKA, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTR, PTCT, ORKA, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, PTCT, ORKA, and MIRM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

Nektar Therapeutics NASDAQ:NKTR

Oruka Therapeutics NASDAQ:ORKA

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTR, PTCT, ORKA, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTR, PTCT, ORKA, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTR, PTCT, ORKA, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, PTCT, ORKA, and MIRM Company Descriptions

Mirum Pharmaceuticals NASDAQ:MIRM

Nektar Therapeutics NASDAQ:NKTR

Oruka Therapeutics NASDAQ:ORKA

PTC Therapeutics NASDAQ:PTCT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools